Author
Muni Kumar Meravath is a seasoned Healthcare Market Research Analyst with over 6 years of experience in the healthc.....
Biosimilars Market: By Drug Class, By Application, By Distribution Channel and Region Forecast 2020-2031
Biosimilars market size was valued at US$ 42.8 billion in 2024 and is projected to reach US$ 136.8 billion by 2031, growing at a CAGR of 18.7% from 2025-2031. Moreover, in the USA, the biosimilar market size was valued at US$ 14.8 billion in 2024 and is projected to reach US$ 73.4 billion by 2031, growing at a CAGR of 23.2$ from 2025 to 2031. Patent expiration of blockbuster biologics used for the treatment of oncology, immunology, and chronic diseases is a key factor surge the growth of biosimilars market. For instance, Abbvie launched the biologic drug Humira, in the year 2002 for the treatment of rheumatoid and psoriatic arthritis had lost their patent in the year 2023 resulted to launch of biosimilars such as Amjevita, Cyltezo, Hyrimoz, Hadlima Abrilada and Hulio. Entry of biosimilars into the market helps in significant cost savings, making life-saving treatments more accessible to patients.
Moreover, favourable regulatory guidelines by FDA and EMA for the biosimilars approvals and rise in the preference for biosimilars among the physicians also bolster the market revenue over the forecast years. Furthermore, the pharmaceutical companies are spending on biosimilars development and manufacturing to meet the increase demand of biosimilars which in turn boost the market.
The growth of the biosimilars market is largely influenced by the expansion of biosimilars beyond oncology and autoimmune diseases. The rising need for cost-effective treatments across a variety of therapeutic areas such as ophthalmology and neurology, also plays a significant role in this market growth. Biosimilars in ophthalmology are being developed to provide affordable alternatives to expensive biologics used in treatment of diabetic retinopathy and age-related macular degeneration.
For Instance, biosimilars of bevacizumab (Avastin) and ranibizumab (Lucentis), possibly transforming eye care. Biosimilars are used for the advanced treatments of neurological diseases such as multiple sclerosis, Alzheimer's disease, and Parkinson's disease. As the high cost of biologics acts as barriers, on the other side the biosimilars will offer affordable and effective therapies to the patients. The increasing use of biosimilars in specialized fields has led to savings for healthcare systems, and also expanded access to critical treatments for patients. This has created significant opportunities for growth of the biosimilar markets.
Intellectual property (IP) issues and patent litigation are the major constraints in the international biosimilars market. Most biologic pharmaceuticals are safeguarded with sophisticated patent schemes, such as secondary patents and exclusivity extensions, pushing back biosimilar launch. Originator businesses typically file lawsuits, pay-for-delay settlements, and regulatory loopholes to preserve market share. Additionally, biosimilar players need to deal with patent environments, involving high levels of legal expertise and capital investments. These barriers raise costs of development and prolong approval schedules, limiting market competition. As a result, patient access to low-cost biosimilars is postponed, thereby inhibiting the potential cost-saving benefits and broader treatment availability.
Study Period
2025-2031Base Year
2024CAGR
24.6%Largest Market
EuropeFastest Growing Market
Asia-Pacific
The drivers for the biosimilars market globally, include rise in the chronic diseases cases such as cancer, diabetes, and autoimmune conditions, which need inexpensive treatment. Since biologics are the most common mode of treatment, their cost makes the potential of biosimilars as low-cost options, thus making the patient accessible. Regulatory support from the FDA and EMA, which have stringent criteria for biosimilar approvals, is also propelling market growth.
In addition, loss of patent exclusivity by top-selling biologics, including monoclonal antibodies and insulin analogs, has increased competition and opened opportunities for biosimilar firms. Cost savings of biosimilars compared with originator biologics also encourage their utilization by healthcare payers and providers trying to manage rising healthcare expenses. Expansion in R&D expenditures, alliances, and manufacturing technology improvement are propelling the efficiency of biosimilar manufacturing, enabling consistent market growth.
Healthcare policies in developing Asia-Pacific and Latin American countries to make healthcare affordable and accessible also drive the market. Expansion in confidence levels around biosimilar safety and efficacy by patients and physicians and expanding awareness are propelling market penetration. In the global world, all these drivers combined are driving the biosimilars market towards a high growth rate and thus it is the most significant segment in biopharmaceuticals.
The biosimilars market worldwide is hindered by number of factors despite growing need for cheaper biologics. The most critical among them is the strict regulatory environment in various sectors that results in long approval times and astronomical development expenses. Biosimilars must be strongly similar to the reference biologics in safety, efficacy, and immunogenicity, an challenging task demanding intensive clinical studies and analytic testing. Doctor-patient unfamiliarity and uncertainty with respect to biosimilar safety and effectiveness and other hurdles restrain adoption. Originator drug brand loyalty and active promotion on the part of originator companies are also barriers to biosimilar market entry. Patent infringement lawsuit and originator biologics' exclusivity rights also act as market entry barriers for biosimilars, and it brings uncertainty to manufacturers. It has reimbursement pressure and price competition for profitability because biosimilars tend to trigger price wars among branded biologics and other generics.
The complexity in mass production of biosimilars, where the most sophisticated biotechnological processes are used with huge investment in plants, is a deciding point in their price, and therefore small firms cannot get a strong foothold. Additionally, slight interchangeability standards in most nations limit direct replacement of biosimilars with their corresponding marketplace vanishing away. All these need to be addressed with regulation harmonization, acknowledgment, and accommodating health care policies to enable the utilization of biosimilars in the world.
Biosimilar market is triggered by massive growth opportunities with drivers such as loss of exclusivity of blockbusters biologics, increasing demand for cost-containment options, and escalating incidence of chronic ailments. At loss of exclusivity for branded biologic medications, biosimilars offer a lucrative market for pharmaceutical companies to produce low-cost substitutes, which decrease healthcare expense and increase patient access. Guidance of regulatory agencies such as the FDA and EMA made it easy for biosimilars to gain approvals, while increased market size, in turn, occurred. Growth opportunities emerging markets of Latin America and the Asia-Pacific region are a great growth opportunity of relatively lower levels of penetration for biologics and increasing disease burdens including cancer, diabetes, and autoimmune diseases.
Besides this, new manufacturing methods and innovative drug delivery systems in biotech enhance biosimilar quality and bioequivalence, thereby making them even more competitive. R&D investments, partnerships, and mergers and acquisitions are driving biosimilar adoption worldwide. Increased acceptability among payers and healthcare professionals, along with favorable reimbursement policy, also drive market growth. Besides this, increased application of biosimilars in hospital formularies and specialty pharmacies will drive demand. In general, the biosimilars market will experience robust growth, with cost savings, expanded access, and improved treatment choices for most disease classes.
Biosimilars business is growing exponentially worldwide due to rising demands for affordable substitutes for biologics, patent erosion for top-selling biologics, and favorable regulatory environment. Healthcare systems and governments globally are encouraging biosimilars as a tool for reducing healthcare expenditure and enhancing patient access to medicines of the biologic category. Oncology, autoimmune disorders, and diabetes are significant therapeutics markets with highest utilization of biosimilars.
Apart from this, R&D spending and biotechnology, process manufacturing, and regulatory compliance innovation geographically located in the U.S., Europe, and Asia-Pacific are driving the market growth. Participation of leading pharma companies and strategic collaborations with CDMOs are driving biosimilar manufacturing and commercialization. Having interchangeables biosimilars present with more flexibilities for substitution is also driving market penetration. Physician pushback, intricate development pipelines, and intellectual property issues remain to influence trends in the market.
Growth possibilities in new markets in Asia and Latin America are reassuring on the back of expanding healthcare expenditure and supportive policy for biosimilars. Through shifting innovation and regulatory developments, the biosimilars marketplace is poised to experience steady expansion as a contesting platform for established as well as new participants.
Report Benchmarks |
Details |
Report Study Period |
2025-2031 |
Market Size in 2024 |
US$ 42.8 billion |
Market Size in 2031 |
US$ 136.8 billion |
Market CAGR |
24.6% |
By Drug Class |
|
By Application |
|
By Distribution Channel |
|
By Region |
|
The global Biosimilars market is motivated by rising demand for cost-effective biologic medicines, the expirations of leading-selling biologics, and the increasing healthcare spend. Approvals from regulatory authorities such as the FDA and EMA that have eased obtaining approvals have spurred growth in the market. The segments treated are oncology, autoimmune conditions, and diabetes, while insulin and monoclonal antibody biosimilars are the drivers of segments. Players like Pfizer, Amgen, and Biocon are involved in R&D and strategic alliances to develop market positions. Constraints of leading-edge manufacturing technologies, regulatory squeeze pressures, and physician adoption limit mass utilization. Growth opportunities with increasing health care infrastructure and pro-biosimilar policies in the Asia-Pacific and Latin American markets are huge. Pricing competition and reimbursement issues are prime drivers for the market trends. In all, the biosimilars market will continue to expand steadily on the strength of innovation, expanding product pipelines, and favorable regulatory support.
Download Free Sample Report
The biosimilars market size was valued at US$ 42.8 billion in 2024 and is projected to reach US$ 136.8 billion by 2031, growing at a CAGR of 18.7% from 2025-2031.
• Patent Expirations of Biologics
• Rising Prevalence of Chronic Diseases
• Cost-Effectiveness and Healthcare Savings.
• Regulatory Support & Streamlined Approval Pathways
• Expanding Therapeutic Applications
• Emerging Markets Growth
• Strategic Partnerships & Collaborations.
1. Executive Summary |
2. Global Biosimilars Market Introduction |
2.1.Global Biosimilars Market - Taxonomy |
2.2.Global Biosimilars Market - Definitions |
2.2.1.Drug Class |
2.2.2.Application |
2.2.3.Distribution Channel |
2.2.4.Region |
3. Global Biosimilars Market Dynamics |
3.1. Drivers |
3.2. Restraints |
3.3. Opportunities/Unmet Needs of the Market |
3.4. Trends |
3.5. Product Landscape |
3.6. New Product Launches |
3.7. Impact of COVID 19 on Market |
4. Global Biosimilars Market Analysis, 2020 - 2024 and Forecast 2025 - 2031 |
4.1. Market Analysis, 2020 - 2024 and Forecast, 2025 - 2031, (Sales Value USD Million) |
4.2. Year-Over-Year (Y-o-Y) Growth Analysis (%) |
4.3. Market Opportunity Analysis |
5. Global Biosimilars Market By Drug Class, 2020 - 2024 and Forecast 2025 - 2031 (Sales Value USD Million) |
5.1. Monoclonal Antibodies |
5.1.1. Market Analysis, 2020 - 2024 and Forecast, 2025 - 2031, (Sales Value USD Million) |
5.1.2. Year-Over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%) |
5.1.3. Market Opportunity Analysis |
5.2. Recombinant Hormones |
5.2.1. Market Analysis, 2020 - 2024 and Forecast, 2025 - 2031, (Sales Value USD Million) |
5.2.2. Year-Over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%) |
5.2.3. Market Opportunity Analysis |
5.3. Recombinant Growth Factors |
5.3.1. Market Analysis, 2020 - 2024 and Forecast, 2025 - 2031, (Sales Value USD Million) |
5.3.2. Year-Over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%) |
5.3.3. Market Opportunity Analysis |
5.4. Immunomodulators |
5.4.1. Market Analysis, 2020 - 2024 and Forecast, 2025 - 2031, (Sales Value USD Million) |
5.4.2. Year-Over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%) |
5.4.3. Market Opportunity Analysis |
5.5. Anti-Inflammatory Agents |
5.5.1. Market Analysis, 2020 - 2024 and Forecast, 2025 - 2031, (Sales Value USD Million) |
5.5.2. Year-Over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%) |
5.5.3. Market Opportunity Analysis |
5.6. Others |
5.6.1. Market Analysis, 2020 - 2024 and Forecast, 2025 - 2031, (Sales Value USD Million) |
5.6.2. Year-Over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%) |
5.6.3. Market Opportunity Analysis |
6. Global Biosimilars Market By Application, 2020 - 2024 and Forecast 2025 - 2031 (Sales Value USD Million) |
6.1. Oncology |
6.1.1. Market Analysis, 2020 - 2024 and Forecast, 2025 - 2031, (Sales Value USD Million) |
6.1.2. Year-Over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%) |
6.1.3. Market Opportunity Analysis |
6.2. Blood Disorders |
6.2.1. Market Analysis, 2020 - 2024 and Forecast, 2025 - 2031, (Sales Value USD Million) |
6.2.2. Year-Over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%) |
6.2.3. Market Opportunity Analysis |
6.3. Autoimmune Diseases |
6.3.1. Market Analysis, 2020 - 2024 and Forecast, 2025 - 2031, (Sales Value USD Million) |
6.3.2. Year-Over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%) |
6.3.3. Market Opportunity Analysis |
6.4. Growth Hormone Deficiency |
6.4.1. Market Analysis, 2020 - 2024 and Forecast, 2025 - 2031, (Sales Value USD Million) |
6.4.2. Year-Over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%) |
6.4.3. Market Opportunity Analysis |
6.5. Infectious Diseases |
6.5.1. Market Analysis, 2020 - 2024 and Forecast, 2025 - 2031, (Sales Value USD Million) |
6.5.2. Year-Over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%) |
6.5.3. Market Opportunity Analysis |
6.6. Diabetes |
6.6.1. Market Analysis, 2020 - 2024 and Forecast, 2025 - 2031, (Sales Value USD Million) |
6.6.2. Year-Over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%) |
6.6.3. Market Opportunity Analysis |
6.7. Others |
6.7.1. Market Analysis, 2020 - 2024 and Forecast, 2025 - 2031, (Sales Value USD Million) |
6.7.2. Year-Over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%) |
6.7.3. Market Opportunity Analysis |
7. Global Biosimilars Market By Distribution Channel, 2020 - 2024 and Forecast 2025 - 2031 (Sales Value USD Million) |
7.1. Hospital Pharmacies |
7.1.1. Market Analysis, 2020 - 2024 and Forecast, 2025 - 2031, (Sales Value USD Million) |
7.1.2. Year-Over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%) |
7.1.3. Market Opportunity Analysis |
7.2. Retail Pharmacies |
7.2.1. Market Analysis, 2020 - 2024 and Forecast, 2025 - 2031, (Sales Value USD Million) |
7.2.2. Year-Over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%) |
7.2.3. Market Opportunity Analysis |
7.3. Online Pharmacies |
7.3.1. Market Analysis, 2020 - 2024 and Forecast, 2025 - 2031, (Sales Value USD Million) |
7.3.2. Year-Over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%) |
7.3.3. Market Opportunity Analysis |
8. Global Biosimilars Market By Region, 2020 - 2024 and Forecast 2025 - 2031 (Sales Value USD Million) |
8.1. North America |
8.1.1. Market Analysis, 2020 - 2024 and Forecast, 2025 - 2031, (Sales Value USD Million) |
8.1.2. Year-Over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%) |
8.1.3. Market Opportunity Analysis |
8.2. Europe |
8.2.1. Market Analysis, 2020 - 2024 and Forecast, 2025 - 2031, (Sales Value USD Million) |
8.2.2. Year-Over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%) |
8.2.3. Market Opportunity Analysis |
8.3. Asia Pacific (APAC) |
8.3.1. Market Analysis, 2020 - 2024 and Forecast, 2025 - 2031, (Sales Value USD Million) |
8.3.2. Year-Over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%) |
8.3.3. Market Opportunity Analysis |
8.4. Middle East and Africa (MEA) |
8.4.1. Market Analysis, 2020 - 2024 and Forecast, 2025 - 2031, (Sales Value USD Million) |
8.4.2. Year-Over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%) |
8.4.3. Market Opportunity Analysis |
8.5. Latin America |
8.5.1. Market Analysis, 2020 - 2024 and Forecast, 2025 - 2031, (Sales Value USD Million) |
8.5.2. Year-Over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%) |
8.5.3. Market Opportunity Analysis |
9. North America Biosimilars Market ,2020 - 2024 and Forecast 2025 - 2031 (Sales Value USD Million) |
9.1. Drug Class Analysis 2020 - 2024 and Forecast 2025 - 2031 by Sales Value USD Million, Y-o-Y Growth (%), and Market Share (%) |
9.1.1.Monoclonal Antibodies |
9.1.2.Recombinant Hormones |
9.1.3.Recombinant Growth Factors |
9.1.4.Immunomodulators |
9.1.5.Anti-Inflammatory Agents |
9.1.6.Others |
9.2. Application Analysis 2020 - 2024 and Forecast 2025 - 2031 by Sales Value USD Million, Y-o-Y Growth (%), and Market Share (%) |
9.2.1.Oncology |
9.2.2.Blood Disorders |
9.2.3.Autoimmune Diseases |
9.2.4.Growth Hormone Deficiency |
9.2.5.Infectious Diseases |
9.2.6.Diabetes |
9.2.7.Others |
9.3. Distribution Channel Analysis 2020 - 2024 and Forecast 2025 - 2031 by Sales Value USD Million, Y-o-Y Growth (%), and Market Share (%) |
9.3.1.Hospital Pharmacies |
9.3.2.Retail Pharmacies |
9.3.3.Online Pharmacies |
9.4. Country Analysis 2020 - 2024 and Forecast 2025 - 2031 by Sales Value USD Million, Y-o-Y Growth (%), and Market Share (%) |
9.4.1.United States of America (USA) |
9.4.2.Canada |
10. Europe Biosimilars Market,2020 - 2024 and Forecast 2025 - 2031 (Sales Value USD Million) |
10.1. Drug Class Analysis and Forecast by Sales Value USD Million, Y-o-Y Growth (%), and Market Share (%) |
10.1.1.Monoclonal Antibodies |
10.1.2.Recombinant Hormones |
10.1.3.Recombinant Growth Factors |
10.1.4.Immunomodulators |
10.1.5.Anti-Inflammatory Agents |
10.1.6.Others |
10.2. Application Analysis 2020 - 2024 and Forecast 2025 - 2031 by Sales Value USD Million, Y-o-Y Growth (%), and Market Share (%) |
10.2.1.Oncology |
10.2.2.Blood Disorders |
10.2.3.Autoimmune Diseases |
10.2.4.Growth Hormone Deficiency |
10.2.5.Infectious Diseases |
10.2.6.Diabetes |
10.2.7.Others |
10.3. Distribution Channel Analysis 2020 - 2024 and Forecast 2025 - 2031 by Sales Value USD Million, Y-o-Y Growth (%), and Market Share (%) |
10.3.1.Hospital Pharmacies |
10.3.2.Retail Pharmacies |
10.3.3.Online Pharmacies |
10.4. Country Analysis 2020 - 2024 and Forecast 2025 - 2031 by Sales Value USD Million, Y-o-Y Growth (%), and Market Share (%) |
10.4.1.Germany |
10.4.2.France |
10.4.3.Italy |
10.4.4.United Kingdom (UK) |
10.4.5.Spain |
10.4.6.Rest of EU |
11. Asia Pacific (APAC) Biosimilars Market ,2020 - 2024 and Forecast 2025 - 2031 (Sales Value USD Million) |
11.1. Drug Class Analysis and Forecast by Sales Value USD Million, Y-o-Y Growth (%), and Market Share (%) |
11.1.1.Monoclonal Antibodies |
11.1.2.Recombinant Hormones |
11.1.3.Recombinant Growth Factors |
11.1.4.Immunomodulators |
11.1.5.Anti-Inflammatory Agents |
11.1.6.Others |
11.2. Application Analysis 2020 - 2024 and Forecast 2025 - 2031 by Sales Value USD Million, Y-o-Y Growth (%), and Market Share (%) |
11.2.1.Oncology |
11.2.2.Blood Disorders |
11.2.3.Autoimmune Diseases |
11.2.4.Growth Hormone Deficiency |
11.2.5.Infectious Diseases |
11.2.6.Diabetes |
11.2.7.Others |
11.3. Distribution Channel Analysis 2020 - 2024 and Forecast 2025 - 2031 by Sales Value USD Million, Y-o-Y Growth (%), and Market Share (%) |
11.3.1.Hospital Pharmacies |
11.3.2.Retail Pharmacies |
11.3.3.Online Pharmacies |
11.4. Country Analysis 2020 - 2024 and Forecast 2025 - 2031 by Sales Value USD Million, Y-o-Y Growth (%), and Market Share (%) |
11.4.1.China |
11.4.2.India |
11.4.3.Australia and New Zealand (ANZ) |
11.4.4.Japan |
11.4.5.Rest of APAC |
12. Middle East and Africa (MEA) Biosimilars Market ,2020 - 2024 and Forecast 2025 - 2031 (Sales Value USD Million) |
12.1. Drug Class Analysis and Forecast by Sales Value USD Million, Y-o-Y Growth (%), and Market Share (%) |
12.1.1.Monoclonal Antibodies |
12.1.2.Recombinant Hormones |
12.1.3.Recombinant Growth Factors |
12.1.4.Immunomodulators |
12.1.5.Anti-Inflammatory Agents |
12.1.6.Others |
12.2. Application Analysis 2020 - 2024 and Forecast 2025 - 2031 by Sales Value USD Million, Y-o-Y Growth (%), and Market Share (%) |
12.2.1.Oncology |
12.2.2.Blood Disorders |
12.2.3.Autoimmune Diseases |
12.2.4.Growth Hormone Deficiency |
12.2.5.Infectious Diseases |
12.2.6.Diabetes |
12.2.7.Others |
12.3. Distribution Channel Analysis 2020 - 2024 and Forecast 2025 - 2031 by Sales Value USD Million, Y-o-Y Growth (%), and Market Share (%) |
12.3.1.Hospital Pharmacies |
12.3.2.Retail Pharmacies |
12.3.3.Online Pharmacies |
12.4. Country Analysis 2020 - 2024 and Forecast 2025 - 2031 by Sales Value USD Million, Y-o-Y Growth (%), and Market Share (%) |
12.4.1.GCC Countries |
12.4.2.South Africa |
12.4.3.Rest of MEA |
13. Latin America Biosimilars Market ,2020 - 2024 and Forecast 2025 - 2031 (Sales Value USD Million) |
13.1. Drug Class Analysis and Forecast by Sales Value USD Million, Y-o-Y Growth (%), and Market Share (%) |
13.1.1.Monoclonal Antibodies |
13.1.2.Recombinant Hormones |
13.1.3.Recombinant Growth Factors |
13.1.4.Immunomodulators |
13.1.5.Anti-Inflammatory Agents |
13.1.6.Others |
13.2. Application Analysis 2020 - 2024 and Forecast 2025 - 2031 by Sales Value USD Million, Y-o-Y Growth (%), and Market Share (%) |
13.2.1.Oncology |
13.2.2.Blood Disorders |
13.2.3.Autoimmune Diseases |
13.2.4.Growth Hormone Deficiency |
13.2.5.Infectious Diseases |
13.2.6.Diabetes |
13.2.7.Others |
13.3. Distribution Channel Analysis 2020 - 2024 and Forecast 2025 - 2031 by Sales Value USD Million, Y-o-Y Growth (%), and Market Share (%) |
13.3.1.Hospital Pharmacies |
13.3.2.Retail Pharmacies |
13.3.3.Online Pharmacies |
13.4. Country Analysis 2020 - 2024 and Forecast 2025 - 2031 by Sales Value USD Million, Y-o-Y Growth (%), and Market Share (%) |
13.4.1.Brazil |
13.4.2.Mexico |
13.4.3.Rest of LA |
14. Competition Landscape |
14.1. Market Player Profiles (Introduction, Brand/Product Sales, Financial Analysis, Product Offerings, Key Developments, Collaborations, M & A, Strategies, and SWOT Analysis) |
14.2.1.Amgen Inc. (U.S.) |
14.2.2.Biocon Ltd. (India) |
14.2.3.Celltrion, Inc. (South Korea) |
14.2.4.Dr. Reddys Laboratories Ltd. (India) |
14.2.5.F. Hoffmann-La Roche Ltd. (Switzerland) |
14.2.6.Pfizer Inc. (U.S.) |
14.2.7.Samsung Bioepis (South Korea) |
14.2.8.Novatis AG (Switzerland) |
14.2.9.Teva Pharmaceuticals Industries Ltd. (Israel) |
15. Research Methodology |
16. Appendix and Abbreviations |
Key Market Players